The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Bryn Mawr Trust CIO Jeffrey Mills lists where to put money to work as Wall Street copes with trade war and recession jitters.Futures Nowread more
The announcement for Target also comes on the heels of a strong quarterly earnings report, where it showed it drove more people to stores and got them to spend more money...Retailread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
The pharmaceutical industry has donated $589,344 to Hillary Clinton's campaign, according to the nonprofit research group Center for Responsive Politics. That's more than any other candidate — despite Clinton's proclamation that she's proud to call the pharmaceutical industry her enemy.
"Price gouging like this in the specialty market is outrageous," Clinton tweeted in September, referring to the now-infamous decision by Turing Pharmaceuticals to raise the price of a decades-old medicine by 5,000 percent overnight. "Tomorrow I'll lay out a plan to take it on."
That was Sept. 21. The IBB, an exchange-traded fund that tracks the biotech industry, promptly sank almost 5 percent. Through this week, it has lost almost 30 percent.
Clinton hasn't let up on drugmakers. Last week, she released a campaign ad directly targeting Valeant Pharmaceuticals, another pharmaceutical company in the crosshairs for hiking prices of old medicines (though Valeant has since run into other troubles).
The contributions in support of Clinton come mainly from individual donors who work for pharmaceutical companies, according to the Center for Responsive Politics. They may also include contributions from political action committees associated with drug companies.
And despite Clinton's antipharma rhetoric, some say she may actually be the industry's safest choice.
"Hillary would probably be positive at this point because at least her policies are identifiable, understandable and likely to get toned down somewhat," said Brian Skorney, an analyst with Robert W. Baird.
Both Bernie Sanders and Donald Trump, Skorney said, would be the most negative, "both because they will utilize rhetoric to attack the industry and make an effort to enact extreme changes that they can't possibly predict the ramifications of."
It's worth noting that Clinton has received the most contributions overall — not just from the pharmaceutical industry. But the drugmakers she's declared as her enemy don't appear to feel the same way.